A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML.

ABSTRACT:

Abstract

Risk stratification using genetics and minimal residual disease has allowed for an increase in the cure rates of pediatric acute myeloid leukemia (pedAML) to up to 70% in contemporary protocols. Nevertheless, ∼30% of patients still experience relapse, indicating a need to optimize stratification strategies. Recently, long noncoding RNA (lncRNA) expression has been shown to hold prognostic power in multiple cancer types. Here, we aimed at refining relapse prediction in pedAML using lncRNA expression. We built a relapse-related lncRNA prognostic signature, named AMLlnc69, using 871 transcriptomes of patients with pedAML obtained from the Therapeutically Applicable Research to Generate Effective Treatments repository. We identified a 69 lncRNA signature AMLlnc69 that is highl

SUBMITTER: Ren Z 

PROVIDER: S-EPMC11226973 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature